Drug Profile
Diabetes therapy - Akesis Pharmaceuticals
Alternative Names: AKP-320Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Akesis Pharmaceuticals
- Class Chromium compounds; Vanadium compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 06 Feb 2009 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in USA (PO)
- 15 May 2006 Akesis and Profil Institute for Clinical Research have signed a consulting agreement for clinical trials in type 2 diabetes
- 14 Feb 2005 Clinical trials in Diabetes mellitus in USA (PO)